

Attorney Docket No.: **ISPH-0543**
Serial No.: **09/851,871**
Page 4

REMARKS

Claims 1-12 are pending in the instant application. All of the claims have been rejected. Claim 1 has been amended. Claims 13-14 were cancelled in a previous amendment. No new matter has been added by this amendment. Reconsideration is respectfully requested in light of the amendment and the following remarks.

I. Rejection of Claims Under 35 U.S.C. 112, paragraph 1

Claims 1-12 were rejected for containing matter which was not described in the specification. The Examiner has objected to the inclusion of Genbank numbers based on the teachings of non-patent documents that were stated to be incorporated by reference into the specification.

The Applicants have amended the claims to recite Genbank numbers that were listed in the original specification.

In view of the amendment, the Applicants submit that all of the matter in the claims is fully supported by the specification and the rejection of the claims under 35 U.S.C. 112, paragraph 1 is traversed.

II. Fees

The Applicants hereby request that the Commissioner charge Deposit Account No. 500252 the fee of \$790.00 for the filing of a Request for Continued Examination, Large Entity. It is believed that no further fee is due. However, if an additional fee is due, the Commissioner is hereby entitled to charge the fee to the Deposit Account listed above citing Reference No. ISPH-0543.

Attorney Docket No.: ISPH-0543
Serial No.: 09/851,871
Page 5

III. Conclusion

Applicants believe that the foregoing comprises a full and complete response to the Office Action of record. Accordingly, favorable reconsideration and subsequent allowance of the pending claims is earnestly solicited.

Respectfully submitted,



Colleen J. McKiernan, PhD
Registration No. 48,570

Date: January 3, 2005

Isis Pharmaceuticals
2922 Faraday Avenue
Carlsbad, CA 92008

Phone: 760-603-2722
Facsimile: 760-603-3820